Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia

E. Pazzucconi, L. Mannucci, L. Mussoni, G. Gianfranceschi, P. Maderna, P. Werba, G. Franceschini, C. R. Sirtori, Elena Tremoli

Research output: Contribution to journalArticlepeer-review


The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12 % fall in total cholesterol and a 20 % increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 %. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.

Original languageEnglish
Pages (from-to)219-223
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Issue number3
Publication statusPublished - Sep 1992


  • Bezafibrate
  • fibrinogen
  • fibrinolysis
  • Hyperlipoproteinaemia
  • plasma lipids
  • platelet aggregation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia'. Together they form a unique fingerprint.

Cite this